Company intelligence / Profile preview

Biohimik

Saransk, Republic of Mordovia, Russia

Ownership: Private
Employees: ~1500
Development stage: Other

Overview

Biohimik is a prominent Russian pharmaceutical manufacturer and a primary production site for the Promomed Group. Located in Saransk, the company was established in 1952 and was one of the first facilities in the USSR to produce penicillin. Today, it specializes in the full-cycle production of essential medicines, including antibiotics, antivirals, and endocrinology products. The company is notably recognized for its role in developing and manufacturing the COVID-19 treatment Areplivir (favipiravir). Biohimik maintains extensive GMP-certified manufacturing capabilities and operates a dedicated R&D center for drug synthesis and formulation development.

Therapeutic areas: EndocrinologyCardiovascularNeurologyInfectious DiseasesOncology
Modalities: Small moleculeBiologicPeptides
Industry: Biotech

Beyond the preview

Go deeper on Biohimik.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biohimik.

Explore the full profile